GG
NWBO

Gofen & Glossberg’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Gofen & Glossberg’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$10K Hold
12,740
– – ﹤0.01% 578
2022
Q3 		$9K Hold
12,740
– – ﹤0.01% 560
2022
Q2 		$8K Hold
12,740
– – ﹤0.01% 565
2022
Q1 		$9K Hold
12,740
– – ﹤0.01% 608
2021
Q4 		$9K Hold
12,740
– – ﹤0.01% 619
2021
Q3 		$16K Hold
12,740
– – ﹤0.01% 610
2021
Q2 		$19K Hold
12,740
– – ﹤0.01% 568
2021
Q1 		$19K Hold
12,740
– – ﹤0.01% 548
2020
Q4 		$19K Buy
+12,740
New +$19K ﹤0.01% 527

Other funds holding NWBO

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
MSAM
Moloney Securities Asset Management Manchester, Missouri $840M AUM 18.11% 1-Year Est. Return
OCG
Opus Capital Group Cincinnati, Ohio $1.03B AUM 20.67% 1-Year Est. Return
WJWM
Williams Jones Wealth Management New York $8.14B AUM 19.32% 1-Year Est. Return
LDB
Lee, Danner & Bass Nashville, Tennessee $1.73B AUM 36.69% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
GWI
Grace & White Inc Ny, New York $632M AUM 34.34% 1-Year Est. Return
AA
AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return
AMG
Advisors Management Group La Crosse, Wisconsin $549M AUM 29.35% 1-Year Est. Return

Gofen & Glossberg's NWBO Position: Q4 2022 in Review

Gofen & Glossberg held its Northwest Biotherapeutics, Inc. Common stock (NWBO) position steady in Q4 2022 at 12,740 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #578.

Gofen & Glossberg first reported a position in NWBO in Q4 2020 and has held it in 9 quarters since. The position peaked at $19K in Q2 2021. 15 funds tracked by Wall St. Rank hold NWBO as of Q4 2022.

  • Gofen & Glossberg held 12,740 shares of Northwest Biotherapeutics, Inc. Common stock worth $10K as of Q4 2022.
  • Gofen & Glossberg left its Northwest Biotherapeutics, Inc. Common stock share count unchanged in Q4 2022.
  • Northwest Biotherapeutics, Inc. Common stock made up ﹤0.01% of Gofen & Glossberg's portfolio in Q4 2022, its #578 holding.
  • Gofen & Glossberg first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q4 2020 and has held it in 9 quarters since.
  • Gofen & Glossberg's Northwest Biotherapeutics, Inc. Common stock position peaked at $19K in Q2 2021.
  • 15 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2022.

Based on Gofen & Glossberg's 13F filing for Q4 2022, filed 13 Jan 2023.